COSCIENS Biopharma Inc (COSCIENS) develops and commercializes a range of pharmaceutical and diagnostic products, particularly in areas with significant unmet medical needs.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

COSCIENS is deeply invested in its research and development (R&D) initiatives, focusing on addressing significant unmet medical needs through innovative solutions. The company's R&D strategy is anchored in its proprietary Pressurized Gas Expanded (PGX) technology, which transforms biopolymers into high-value materials. This technology is central to developing stable, high-purity formulations that enhance the efficacy and shelf life of its products. A major focus is the exploration and development of avenanthramides and oat beta glucan, with potential therapeutic applications in various conditions. The company employs advanced chromatography purification technology to produce pharmaceutical-grade avenanthramides for trials. Additionally, COSCIENS aims to extend the applications of oat beta glucan beyond personal care into the nutraceutical and pharmaceutical sectors. Despite discontinuing certain programs due to cost and timeline considerations, COSCIENS continues to prioritize R&D as a core component of its growth strategy. The merger with Ceapro Inc. enhances its capabilities, providing additional resources and expertise to drive R&D initiatives forward. The R&D unit of COSCIENS Biopharma Inc. is responsible for managing the company's research and development activities, focusing on the exploration and development of avenanthramides and oat beta glucan, and employing advanced chromatography purification technology for pharmaceutical-grade production. In FY2024, the company invested US$8.3 million in research and development, accounting for 86.6% of its revenue.